Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
2022 · The Lancet · 395 citations
https://doi.org/10.1016/s0140-6736(22)00519-0
R
Ronak Miladi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
25
Papers
562
Citations
7
h-index
7
i10-index
Ronak Miladi is an academic researcher from Kermanshah University of Medical Sciences. The author has contributed to research in topics: COVID-19 Clinical Research Studies & Antibiotic Use and Resistance & Antibiotic Resistance in Bacteria. The author has an h-index of 7, co-authored 22 publications.
ORCID: 0000-0002-3330-3142Papers by this author
worksEfficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial
2021 · Journal of Antimicrobial Chemotherapy · 22 citations
https://doi.org/10.1093/jac/dkab152
National Update on Healthcare-Associated Infections in Iran for 2023—Based on the Iranian Nosocomial Infections Surveillance (INIS) System
2025 · Journal of Epidemiology and Global Health · 0 citations
https://doi.org/10.1007/s44197-025-00462-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat